BIOA
BioAge Labs, Inc.
Price Chart
Latest Quote
$19.99
-0.50 (-2.44%)
Current Price
| Previous Close | $20.49 |
| Open | $20.49 |
| Day High | $21.27 |
| Day Low | $19.61 |
| Volume | 464,797 |
Stock Information
| Shares Outstanding | 44.45M |
| Total Debt | $4.03M |
| Cash Equivalents | $383.19M |
| Revenue | $10.32M |
| Net Income | $-89.93M |
| Sector | Healthcare |
| Industry | Drug Manufacturers - Specialty & Generic |
| Market Cap | $888.61M |
| EPS (TTM) | $-2.40 |
| Exchange | NMS |
đ Comprehensive Analysis
Company Data
| Enterprise Value | $531.68M |
| Sales | $10.32M |
| Income | $-89.93M |
| Book/sh | $8.54 |
| Cash/sh | $8.62 |
| Employees | 60 |
Financial Ratios
| Quick Ratio | 24.38 |
| Current Ratio | 24.76 |
| Debt/Eq | 1.06 |
Returns & Margins
| ROA | -17.15% |
| ROE | -25.98% |
| Operating Margin | -915.40% |
Ownership
| Insider Ownership | 2.44% |
| Institutional Ownership | 85.51% |
| Insider & Institutional transactions data not available | |
Valuation Ratios
| Forward P/E | -9.70 |
| P/S | 86.14 |
| P/B | 2.34 |
Analyst Data
| Recommendation | buy |
| Target Price | $49.50 |
Technical Indicators
| SMA20 | $17.05 |
| SMA50 | $17.33 |
| SMA200 | $13.92 |
| RSI | 64.55 |
| ATR | 1.2856 |
| Shares Float | 33.69M |
| Short Float | 4.55% |
| Short Ratio | 4.31 |
| Rel Volume | 1.13 |
Performance History
| Week | +29.13% |
| Month | +30.31% |
| Quarter | +3.25% |
| 6 Months | +60.43% |
| YTD | +55.81% |
| Year | +356.39% |
| 10 Years | +9.18% |
Stock Score:
â Premium
Based on debt, profitability, growth, and cash flow metrics
â Premium Feature
Sign up for free to view detailed scoring breakdown â premium is free during our trial period!
Recent Price History
| Date | Close | Volume |
|---|---|---|
| 2026-06-17 | $19.99 | 495,600 |
| 2026-06-16 | $20.49 | 666,300 |
| 2026-06-15 | $19.84 | 746,100 |
| 2026-06-12 | $18.04 | 436,900 |
| 2026-06-11 | $16.45 | 629,300 |
| 2026-06-10 | $15.48 | 358,900 |
| 2026-06-09 | $15.80 | 177,800 |
| 2026-06-08 | $15.51 | 304,800 |
| 2026-06-05 | $15.70 | 375,900 |
| 2026-06-04 | $17.02 | 271,800 |
| 2026-06-03 | $16.04 | 256,900 |
| 2026-06-02 | $16.54 | 382,400 |
| 2026-06-01 | $17.20 | 319,100 |
| 2026-05-29 | $17.29 | 234,200 |
| 2026-05-28 | $17.05 | 230,700 |
| 2026-05-27 | $16.95 | 1,402,000 |
| 2026-05-26 | $16.20 | 586,300 |
| 2026-05-22 | $16.61 | 211,100 |
| 2026-05-21 | $16.74 | 315,600 |
| 2026-05-20 | $16.11 | 340,100 |
| 2026-05-19 | $16.37 | 520,100 |
| 2026-05-18 | $15.34 | 451,600 |
About BioAge Labs, Inc.
BioAge Labs, Inc., a clinical-stage biopharmaceutical company, develops therapeutic product candidates for metabolic diseases. The company's technology platform and differentiated human datasets that allows users to identify targets based on insights into molecular changes that drive aging. Its lead product candidate includes BGE-102, an orally available brain-penetrant small-molecule NLRP3 inhibitor which is in Phase 1 clinical trail for the treatment of atherosclerotic cardiovascular disease, as well as for the treatment of diabetic macular edema and geographic atrophy; and develops APJ agonists for obesity, including programs targeting both oral and parenteral administration. The company has collaboration agreement with Novartis Pharma AG to identify and validate novel therapeutic drug targets by investigating the biological mechanisms that drive diseases related to aging and mediate. BioAge Labs, Inc. was incorporated in 2015 and is headquartered in Emeryville, California.
đ° Latest News
BioAge Labs Eyes Key BGE-102 Readouts in Heart Risk and Diabetic Eye Disease
MarketBeat âĸ 2026-06-06T12:04:44Z
Is BioAge Labs, Inc. (BIOA) a Top Longevity Biotech Stock to Watch After New Analyst Coverage?
Insider Monkey âĸ 2026-05-20T20:43:26Z
This CoinShares Analyst Begins Coverage On A Bullish Note; Here Are Top 2 Initiations For Wednesday
Benzinga âĸ 2026-05-13T17:43:43Z
AMD, Under Armour downgraded: Wall Street's top analyst calls
The Fly âĸ 2026-05-13T13:35:33Z
Earnings Update: Here's Why Analysts Just Lifted Their BioAge Labs, Inc. (NASDAQ:BIOA) Price Target To US$53.33
Simply Wall St. âĸ 2026-05-13T12:47:10Z
Here Are Wednesdayâs Top Wall Street Analyst Research Calls: Advanced Micro Devices, Akamai Technologies, HEICO, Johnson & Johnson, MasTec, MercadoLibre, Sandisk, Snap, and More
24/7 Wall St. âĸ 2026-05-13T11:54:40Z
BioAge Labs R&D Day: BGE-102 Phase I Shows Big hs-CRP Drops, Sets Up Cardio & DME POC Trials
MarketBeat âĸ 2026-05-08T19:12:30Z
BioAge Labs Touts Phase 1 BGE-102 Data, Citing 86% hs-CRP Drop and Clean Safety Profile
MarketBeat âĸ 2026-04-24T16:43:20Z
Has Amarin (AMRN) Outpaced Other Medical Stocks This Year?
Zacks âĸ 2026-04-23T13:40:02Z
Wall Street Analysts Predict an 183.67% Upside in BioAge Labs, Inc. (BIOA): Here's What You Should Know
Zacks âĸ 2026-04-21T13:55:03Z
Period:
Loading...
Income Statement (Annual)
| Metric | 2025-12-31 | 2024-12-31 | 2023-12-31 | 2022-12-31 |
|---|---|---|---|---|
| Revenue | ||||
| Total Revenue | $8,995,000 | $0 | $0 | $0 |
| Operating Revenue | $8,995,000 | $0 | $0 | $0 |
| Expenses | ||||
| Interest Expense | $697,000 | $2,367,000 | $7,794,000 | $241,000 |
| Total Expenses | $101,775,000 | $78,194,000 | $48,400,000 | $39,969,000 |
| Other Income Expense | $-214,000 | $-177,000 | $-10,091,000 | $23,000 |
| Net Non Operating Interest Income Expense | $12,389,000 | $7,262,000 | $-5,363,000 | $224,000 |
| Interest Expense Non Operating | $697,000 | $2,367,000 | $7,794,000 | $241,000 |
| Operating Expense | $101,775,000 | $78,194,000 | $48,400,000 | $39,969,000 |
| General And Administrative Expense | $27,809,000 | $19,158,000 | $14,514,000 | $9,447,000 |
| Income & Earnings | ||||
| Net Income From Continuing Operation Net Minority Interest | $-80,605,000 | $-71,109,000 | $-63,854,000 | $-39,722,000 |
| Net Interest Income | $12,389,000 | $7,262,000 | $-5,363,000 | $224,000 |
| Interest Income | $13,086,000 | $9,629,000 | $2,431,000 | $465,000 |
| Normalized Income | $-80,391,000 | $-70,932,000 | $-53,763,000 | $-39,745,000 |
| Net Income From Continuing And Discontinued Operation | $-80,605,000 | $-71,109,000 | $-63,854,000 | $-39,722,000 |
| Total Operating Income As Reported | $-92,780,000 | $-78,194,000 | $-48,400,000 | $-39,969,000 |
| Net Income Common Stockholders | $-80,605,000 | $-71,109,000 | $-63,854,000 | $-39,722,000 |
| Net Income | $-80,605,000 | $-71,109,000 | $-63,854,000 | $-39,722,000 |
| Net Income Including Noncontrolling Interests | $-80,605,000 | $-71,109,000 | $-63,854,000 | $-39,722,000 |
| Net Income Continuous Operations | $-80,605,000 | $-71,109,000 | $-63,854,000 | $-39,722,000 |
| Pretax Income | $-80,605,000 | $-71,109,000 | $-63,854,000 | $-39,722,000 |
| Special Income Charges | $0 | $-250,000 | $0 | - |
| Interest Income Non Operating | $13,086,000 | $9,629,000 | $2,431,000 | $465,000 |
| Operating Income | $-92,780,000 | $-78,194,000 | $-48,400,000 | $-39,969,000 |
| Per Share | ||||
| Diluted EPS | $-2.24 | $-6.63 | $-3.17 | $-23.76 |
| Basic EPS | $-2.24 | $-6.63 | $-3.17 | $-23.76 |
| Other | ||||
| Tax Effect Of Unusual Items | $0 | $0 | $0 | $0 |
| Tax Rate For Calcs | $0 | $0 | $0 | $0 |
| Normalized EBITDA (Bullshit earnings) | $-79,481,000 | $-68,398,000 | $-45,807,000 | $-39,375,000 |
| Total Unusual Items | $-214,000 | $-177,000 | $-10,091,000 | $23,000 |
| Total Unusual Items Excluding Goodwill | $-214,000 | $-177,000 | $-10,091,000 | $23,000 |
| Reconciled Depreciation | $213,000 | $167,000 | $162,000 | $129,000 |
| EBITDA (Bullshit earnings) | $-79,695,000 | $-68,575,000 | $-55,898,000 | $-39,352,000 |
| EBIT | $-79,908,000 | $-68,742,000 | $-56,060,000 | $-39,481,000 |
| Diluted Average Shares | $35,932,914 | $10,726,521 | $20,119,816 | $1,671,761 |
| Basic Average Shares | $35,932,914 | $10,726,521 | $20,119,816 | $1,671,761 |
| Diluted NI Availto Com Stockholders | $-80,605,000 | $-71,109,000 | $-63,854,000 | $-39,722,000 |
| Gain On Sale Of Security | $-214,000 | $73,000 | $-10,091,000 | $23,000 |
| Research And Development | $73,966,000 | $59,036,000 | $33,886,000 | $30,522,000 |
| Selling General And Administration | $27,809,000 | $19,158,000 | $14,514,000 | $9,447,000 |
| Other Gand A | $27,809,000 | $19,158,000 | $14,514,000 | $9,447,000 |
| Other Special Charges | - | $250,000 | - | - |
Fetched: 2026-06-17
Balance Sheet (Annual)
| Metric | 2025-12-31 | 2024-12-31 | 2023-12-31 | 2022-12-31 |
|---|---|---|---|---|
| Assets | ||||
| Net Tangible Assets | $272,051,000 | $323,127,000 | $-173,396,000 | $-112,559,000 |
| Total Assets | $294,889,000 | $358,234,000 | $25,924,000 | $28,429,000 |
| Total Non Current Assets | $8,096,000 | $1,131,000 | $618,000 | $399,000 |
| Other Non Current Assets | $216,000 | $240,000 | - | $25,000 |
| Investmentin Financial Assets | $4,032,000 | $0 | - | - |
| Current Assets | $286,793,000 | $357,103,000 | $25,306,000 | $28,030,000 |
| Other Current Assets | $4,926,000 | $2,754,000 | $349,000 | $386,000 |
| Receivables | $769,000 | $0 | - | - |
| Accounts Receivable | $769,000 | $0 | - | - |
| Cash Cash Equivalents And Short Term Investments | $281,098,000 | $354,349,000 | $21,644,000 | $27,644,000 |
| Cash And Cash Equivalents | $188,888,000 | $354,349,000 | $21,644,000 | $27,644,000 |
| Restricted Cash | - | $0 | $3,313,000 | $0 |
| Debt | ||||
| Total Debt | $5,560,000 | $8,704,000 | $53,252,000 | $2,468,000 |
| Long Term Debt And Capital Lease Obligation | $2,330,000 | $2,502,000 | $8,201,000 | $2,252,000 |
| Current Debt And Capital Lease Obligation | $3,230,000 | $6,202,000 | $45,051,000 | $216,000 |
| Current Debt | $2,648,000 | $6,000,000 | $44,857,000 | $167,000 |
| Other Current Borrowings | $2,648,000 | $6,000,000 | $44,857,000 | $167,000 |
| Long Term Debt | - | $2,502,000 | $8,201,000 | $2,252,000 |
| Net Debt | - | - | $31,414,000 | - |
| Liabilities | ||||
| Total Liabilities Net Minority Interest | $22,838,000 | $35,107,000 | $199,320,000 | $140,988,000 |
| Total Non Current Liabilities Net Minority Interest | $2,700,000 | $7,332,000 | $141,152,000 | $135,127,000 |
| Derivative Product Liabilities | $370,000 | $156,000 | $229,000 | $153,000 |
| Non Current Deferred Liabilities | $0 | $4,674,000 | $0 | - |
| Current Liabilities | $20,138,000 | $27,775,000 | $58,168,000 | $5,861,000 |
| Other Current Liabilities | $525,000 | $417,000 | $1,389,000 | $24,000 |
| Current Deferred Liabilities | $5,754,000 | $7,826,000 | $3,313,000 | $0 |
| Payables And Accrued Expenses | $10,629,000 | $13,330,000 | $8,415,000 | $5,621,000 |
| Payables | $2,674,000 | $1,996,000 | $1,866,000 | $2,261,000 |
| Accounts Payable | $2,674,000 | $1,996,000 | $1,866,000 | $2,261,000 |
| Equity | ||||
| Common Stock Equity | $272,051,000 | $323,127,000 | $-173,396,000 | $-112,559,000 |
| Total Equity Gross Minority Interest | $272,051,000 | $323,127,000 | $-173,396,000 | $-112,559,000 |
| Stockholders Equity | $272,051,000 | $323,127,000 | $-173,396,000 | $-112,559,000 |
| Gains Losses Not Affecting Retained Earnings | $278,000 | $245,000 | $164,000 | $167,000 |
| Other Equity Adjustments | $278,000 | $245,000 | $164,000 | $167,000 |
| Retained Earnings | $-333,416,000 | $-252,811,000 | $-181,702,000 | $-117,848,000 |
| Preferred Securities Outside Stock Equity | - | $0 | $132,722,000 | $132,722,000 |
| Other | ||||
| Ordinary Shares Number | $37,386,908 | $35,850,037 | $34,167,184 | $34,167,184 |
| Share Issued | $37,386,908 | $35,850,037 | $34,167,184 | $34,167,184 |
| Tangible Book Value | $272,051,000 | $323,127,000 | $-173,396,000 | $-112,559,000 |
| Invested Capital | $274,699,000 | $331,629,000 | $-120,338,000 | $-110,140,000 |
| Working Capital | $266,655,000 | $329,328,000 | $-32,862,000 | $22,169,000 |
| Capital Lease Obligations | $2,912,000 | $202,000 | $194,000 | $49,000 |
| Total Capitalization | $272,051,000 | $325,629,000 | $-165,195,000 | $-110,307,000 |
| Additional Paid In Capital | $605,189,000 | $575,693,000 | $8,142,000 | $5,122,000 |
| Capital Stock | $0 | $0 | $0 | $0 |
| Common Stock | $0 | $0 | $0 | $0 |
| Preferred Stock | $0 | $0 | - | - |
| Non Current Deferred Revenue | $0 | $4,674,000 | $0 | - |
| Long Term Capital Lease Obligation | $2,330,000 | $0 | - | - |
| Current Deferred Revenue | $5,754,000 | $7,826,000 | $3,313,000 | $0 |
| Current Capital Lease Obligation | $582,000 | $202,000 | $194,000 | $49,000 |
| Current Accrued Expenses | $7,955,000 | $11,334,000 | $6,549,000 | $3,360,000 |
| Investments And Advances | $4,132,000 | $100,000 | $100,000 | $0 |
| Other Investments | $100,000 | $100,000 | $100,000 | $0 |
| Available For Sale Securities | $4,032,000 | - | - | - |
| Net PPE | $3,748,000 | $791,000 | $518,000 | $374,000 |
| Accumulated Depreciation | $-482,000 | $-371,000 | $-419,000 | $-253,000 |
| Gross PPE | $4,230,000 | $1,162,000 | $937,000 | $627,000 |
| Leases | $161,000 | $0 | - | - |
| Construction In Progress | $22,000 | $176,000 | $0 | - |
| Other Properties | $3,808,000 | $869,000 | $561,000 | $322,000 |
| Machinery Furniture Equipment | $239,000 | $117,000 | $376,000 | $305,000 |
| Properties | $0 | $0 | - | - |
| Other Short Term Investments | $92,210,000 | $0 | - | - |
Fetched: 2026-06-17
Cash Flow Statement (Annual)
| Metric | 2025-12-31 | 2024-12-31 | 2023-12-31 | 2022-12-31 |
|---|---|---|---|---|
| Free Cash Flow | ||||
| Free Cash Flow | $-82,346,000 | $-51,888,000 | $-37,528,000 | $-36,284,000 |
| Operating Activities | ||||
| Operating Cash Flow | $-81,627,000 | $-51,522,000 | $-37,362,000 | $-36,181,000 |
| Cash Flow From Continuing Operating Activities | $-81,627,000 | $-51,522,000 | $-37,362,000 | $-36,181,000 |
| Operating Gains Losses | $237,000 | $232,000 | $10,091,000 | $-23,000 |
| Investing Activities | ||||
| Capital Expenditure | $-719,000 | $-366,000 | $-166,000 | $-103,000 |
| Investing Cash Flow | $-95,216,000 | $-366,000 | $-266,000 | $-103,000 |
| Cash Flow From Continuing Investing Activities | $-95,216,000 | $-366,000 | $-266,000 | $-103,000 |
| Financing Activities | ||||
| Issuance Of Capital Stock | $17,155,000 | $391,619,000 | $0 | - |
| Financing Cash Flow | $11,469,000 | $381,199,000 | $34,941,000 | $2,499,000 |
| Cash Flow From Continuing Financing Activities | $11,469,000 | $381,199,000 | $34,941,000 | $2,499,000 |
| Net Other Financing Charges | $-400,000 | $-5,054,000 | $-63,000 | $-45,000 |
| Net Preferred Stock Issuance | $0 | $170,000,000 | $0 | - |
| Preferred Stock Issuance | $0 | $170,000,000 | $0 | - |
| Net Common Stock Issuance | $17,155,000 | $221,619,000 | $0 | - |
| Common Stock Issuance | $17,155,000 | $221,619,000 | $0 | - |
| Other | ||||
| Repayment Of Debt | $-6,000,000 | $-6,000,000 | $-1,000,000 | $0 |
| Interest Paid Supplemental Data | $611,000 | $1,420,000 | $1,155,000 | $129,000 |
| End Cash Position | $188,888,000 | $354,349,000 | $24,957,000 | $27,644,000 |
| Beginning Cash Position | $354,349,000 | $24,957,000 | $27,644,000 | $61,183,000 |
| Effect Of Exchange Rate Changes | $-87,000 | $81,000 | $0 | $246,000 |
| Changes In Cash | $-165,374,000 | $329,311,000 | $-2,687,000 | $-33,785,000 |
| Proceeds From Stock Option Exercised | $714,000 | $634,000 | $4,000 | $44,000 |
| Net Issuance Payments Of Debt | $-6,000,000 | $-6,000,000 | $35,000,000 | $2,500,000 |
| Net Long Term Debt Issuance | $-6,000,000 | $-6,000,000 | $11,500,000 | $2,500,000 |
| Long Term Debt Payments | $-6,000,000 | $-6,000,000 | $-1,000,000 | $0 |
| Net Investment Purchase And Sale | $-94,497,000 | $0 | $-100,000 | $0 |
| Sale Of Investment | $60,250,000 | $0 | - | - |
| Purchase Of Investment | $-154,747,000 | $0 | $-100,000 | $0 |
| Net PPE Purchase And Sale | $-719,000 | $-366,000 | $-166,000 | $-103,000 |
| Purchase Of PPE | $-719,000 | $-366,000 | $-166,000 | $-103,000 |
| Change In Working Capital | $-11,828,000 | $11,176,000 | $6,710,000 | $795,000 |
| Change In Other Working Capital | $-6,746,000 | $9,187,000 | $3,313,000 | - |
| Change In Other Current Assets | $24,000 | $-240,000 | $25,000 | $352,000 |
| Change In Payables And Accrued Expense | $-2,624,000 | $4,634,000 | $3,335,000 | $473,000 |
| Change In Accrued Expense | $-3,412,000 | $4,628,000 | $3,728,000 | $-521,000 |
| Change In Payable | $788,000 | $6,000 | $-393,000 | $994,000 |
| Change In Account Payable | $788,000 | $6,000 | $-393,000 | $994,000 |
| Change In Prepaid Assets | $-1,713,000 | $-2,405,000 | $37,000 | $-30,000 |
| Change In Receivables | $-769,000 | $0 | - | - |
| Changes In Account Receivables | $-769,000 | $0 | - | - |
| Other Non Cash Items | $-1,335,000 | $1,033,000 | $6,513,000 | $100,000 |
| Stock Based Compensation | $11,691,000 | $6,979,000 | $3,016,000 | $2,540,000 |
| Depreciation Amortization Depletion | $213,000 | $167,000 | $162,000 | $129,000 |
| Depreciation And Amortization | $213,000 | $167,000 | $162,000 | $129,000 |
| Depreciation | $213,000 | $167,000 | $162,000 | $129,000 |
| Gain Loss On Investment Securities | $214,000 | $-73,000 | $10,091,000 | $-23,000 |
| Gain Loss On Sale Of PPE | $23,000 | $55,000 | $0 | - |
| Net Income From Continuing Operations | $-80,605,000 | $-71,109,000 | $-63,854,000 | $-39,722,000 |
| Issuance Of Debt | - | $0 | $36,000,000 | $2,500,000 |
| Net Short Term Debt Issuance | - | $0 | $23,500,000 | $0 |
| Short Term Debt Issuance | - | $0 | $23,500,000 | $0 |
| Long Term Debt Issuance | - | $0 | $12,500,000 | $2,500,000 |
Fetched: 2026-06-17